Vermilion therapeutics aims to treat many intractable diseases for which there has been no curable drugs by now.

Vermilion Therapeutics Inc. is an academia-based startup in which goal for research and development of pharmaceutical drugs activated with photo-catalytic agents and technology with light and ultrasonics. The basic technology studies so far have shown that it will remove various amyloids in CNS diseases, including Alzheimer's disease, and systemic amyloidosis by the accumulation and aggregation of insoluble proteins and peptides. By removing the aggregation of these insoluble proteins and peptides using a Photo / ultrasonic-response catalysts, Vermilion Therapeutics Inc. aims to treat many intractable diseases for which there has been no curable drugs by now.

We named it Vermilion Therapeutics in the image color of “Red gate” of the University of Tokyo, where this technology was discovered and started to be developed, meaning of the gate color name of "Vermilion". Also, since ancient times, "Vermilion" has been believed to be a color that can remove human illnesses and evil spirits and brings happiness, so we want to become a company that can save suffering people from those intractable diseases.

In addition to the treatment of amyloidosis using the light-catalytic technology, we would like also to take on the challenge of oncology and infectious diseases. We aim to discover drugs using new drug-discovery technology based on computational chemistry using AI technology. We would like to contribute to our society by research and development of new drugs in those areas where unmet medical needs are high and there are no therapeutic drugs exist.

Shinichi Torii, Ph.D. CEO & President